Keywords:
Empagliflozin/metformin Hydrochloride, Empagliflozin/metformin Hydrochloride’s R&D Progress, Mechanism of Action for Empagliflozin/metformin Hydrochloride, drug target for Empagliflozin/metformin Hydrochloride.
Description:
This article summarized the latest R&D progress of Empagliflozin/metformin Hydrochloride, the Mechanism of Action for Empagliflozin/metformin Hydrochloride, and the drug target R&D trends for Empagliflozin/metformin Hydrochloride.
Text:
Empagliflozin/metformin Hydrochloride‘s R&D Progress
Empagliflozin/metformin hydrochloride is a small molecule drug used in the treatment of Diabetes Mellitus, Type 2. It is a combination therapy that targets two specific proteins, PRKAB1 and SGLT2, which are involved in the regulation of glucose metabolism. The drug falls under the therapeutic areas of Endocrinology and Metabolic Disease.
The originator organization of Empagliflozin/metformin hydrochloride is Boehringer Ingelheim GmbH, a pharmaceutical company known for its expertise in the development of innovative drugs. The drug has received approval in multiple countries, where it was first approved in May 2015.
Empagliflozin/metformin hydrochloride is primarily used to manage Diabetes Mellitus, Type 2, a chronic condition characterized by high blood sugar levels due to insulin resistance or insufficient insulin production. By targeting PRKAB1 and SGLT2, the drug helps to improve glycemic control by reducing glucose reabsorption in the kidneys and increasing glucose excretion through urine.
As a small molecule drug, Empagliflozin/metformin hydrochloride is designed to be easily absorbed and distributed throughout the body. Its small size allows it to interact with specific molecular targets, leading to the desired therapeutic effects. The drug has undergone rigorous clinical trials, resulting in its approval for use in patients with Diabetes Mellitus, Type 2.
The approval of Empagliflozin/metformin hydrochloride in multiple countries, highlights its global significance in the treatment of Diabetes Mellitus, Type 2. Its approval in Norway in 2015 marked an important milestone in the availability of this drug for patients in need.
Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.
Mechanism of Action for Empagliflozin/metformin Hydrochloride: PRKAB1 activators and SGLT2 inhibitors
PRKAB1 activators are substances or drugs that stimulate the activation of PRKAB1, which is a gene that codes for a protein called AMP-activated protein kinase (AMPK). AMPK is an enzyme that plays a crucial role in regulating energy metabolism in cells. It is involved in processes such as glucose uptake, fatty acid oxidation, and mitochondrial biogenesis.
From a biomedical perspective, PRKAB1 activators can be used as potential therapeutic agents for various metabolic disorders, including diabetes, obesity, and cardiovascular diseases. By activating PRKAB1 and subsequently AMPK, these activators can enhance glucose uptake in cells, promote fatty acid oxidation, and improve insulin sensitivity. This can help regulate blood glucose levels, reduce body weight, and improve overall metabolic health.
SGLT2 inhibitors, on the other hand, are a class of drugs used in the treatment of type 2 diabetes. SGLT2 stands for sodium-glucose cotransporter 2, which is a protein responsible for reabsorbing glucose in the kidneys. By inhibiting SGLT2, these drugs prevent the reabsorption of glucose and promote its excretion through urine, leading to a decrease in blood glucose levels.
From a biomedical perspective, SGLT2 inhibitors work by targeting the renal glucose reabsorption pathway, which is a major contributor to elevated blood glucose levels in individuals with type 2 diabetes. By blocking SGLT2, these inhibitors help lower blood glucose levels and promote glycosuria (glucose excretion in urine), thereby improving glycemic control. Additionally, SGLT2 inhibitors may also have beneficial effects on weight loss and blood pressure reduction.
In summary, PRKAB1 activators stimulate the activation of AMPK, which regulates energy metabolism, while SGLT2 inhibitors target the renal glucose reabsorption pathway to lower blood glucose levels. Both have potential therapeutic applications in the field of biomedicine, particularly in the management of metabolic disorders and diabetes.
Drug Target R&D Trends for Empagliflozin/metformin Hydrochloride
PRKAB1 and SGLT2 are both important components in the human body’s metabolic processes. PRKAB1, also known as AMP-activated protein kinase subunit beta-1, plays a crucial role in regulating energy balance and metabolism. It helps activate cellular energy production and inhibits energy-consuming pathways. On the other hand, SGLT2, or sodium-glucose cotransporter 2, is responsible for reabsorbing glucose in the kidneys. Inhibiting SGLT2 can lead to increased glucose excretion in urine, thereby reducing blood glucose levels. The combination of PRKAB1 and SGLT2 modulation can potentially offer therapeutic benefits in managing metabolic disorders such as diabetes and obesity.
According to Patsnap Synapse, as of 10 Oct 2023, there are a total of 13 PRKAB1 + SGLT2 drugs worldwide, from 17 organizations, covering 6 indications, and conducting 241 clinical trials.
Please click on the picture link below for free registration or log in directly if you have a freemium account, you can browse the latest research progress on drugs, indications, organizations, clinical trials, clinical results, and drug patents related to this target
Conclusion
In summary, Empagliflozin/metformin hydrochloride is a small molecule drug developed by Boehringer Ingelheim GmbH for the treatment of Diabetes Mellitus, Type 2. It targets PRKAB1 and SGLT2 proteins and has been approved in various countries. Its approval signifies its effectiveness in managing this chronic condition and provides a valuable treatment option for patients worldwide.
